60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 30, 2025 14:20 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) closed a $1.043M registered direct offering, issuing common stock and short-term warrants to fund working capital.
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 29, 2025 08:00 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) announces a $1.043M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
January 28, 2025 08:01 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
January 08, 2025 08:02 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
December 23, 2024 08:57 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
December 11, 2024 08:56 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
November 14, 2024 14:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
October 03, 2024 09:02 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 06, 2024 08:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals closes a $4M private placement for working capital and R&D, with stock and warrants priced at $1.38 per share.
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 04, 2024 08:00 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.